Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease

American Journal of Gastroenterology

Volumn 100, Issue 9, 2005, Pages 2031-2035

  Bernstein, Michael ^a   Irwin, Sue ^a   Greenberg, Gordon R ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CITRATE CALCIUM; CORTICOSTEROID; ETIDRONIC ACID; INFLIXIMAB; METHOTREXATE; PAMIDRONIC ACID; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ACTIVITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERITIS; FEMALE; FEMUR NECK; HUMAN; IMMUNOTHERAPY; LUMBAR SPINE; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; DRUG EFFECT; MIDDLE AGED; PHOTON ABSORPTIOMETRY;

ABSORPTIOMETRY, PHOTON; ADULT; ANTIBODIES, MONOCLONAL; BONE DENSITY; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED;

EID: 27744495914     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.50219.x     Document Type: Article

References (34)

1. Adachi JD Rostom A. Metabolic bone disease in adults with inflammatory bowel disease. Inflamm Bowel Dis 1999 5 : 200 11.
2. Lichtenstein GR. Evaluation of bone mineral density in inflammatory bowel disease: Current safety focus. Am J Gastroenterol 2003 98 : S24 S30.
3. Bjarnson I. Metabolic bone disease in patients with inflammatory bowel disease. Rheumatology 1999 38 : 801 6.
4. Siffledeen JS Fedorak RN Siminoski K, et al. Risk factors associated with low bone mineral density in patients with Crohn's disease. Inflamm Bowel Dis 2004 10 : 220 8.
5. Reid IR. Glucocorticoid osteoporosis-mechanisms and management. Eur J Endocrinol 1997 137 : 209 17.
6. Vestergaard P Krough K Rejnmark L, et al. Fracture risk is increased in Crohn's disease but not in ulcerative colitis. Gut 2000 46 : 176 81.
7. Bernstein CN Blanchard JF Metge C, et al. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol 2003 98 : 1797 801.
8. Schoon EJ Blok BM Geerling BJ, et al. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 1997 7 : 909 20.
9. Roux S Orcel P. Bone loss: Factors that regulate osteoclast differentiation-an update. Arthritis Res 2000 2 : 451 6.
10. Abu-Amer Y Erdmann J Alexopoulou L, et al. Tumor necrosis factor types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 2000 275 : 27307 10.
11. Zhang YH Heulsmann A Tondravi MM, et al. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 2001 276 : 563 8.
12. Targan SR Hanauer SB van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997 337 : 1029 35.
13. Hanauer SB Feagan BG Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002 359 : 1541 9.
14. Sands BE Anderson FH Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004 350 : 876 85.
15. Ettinger B Black DM Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 1999 282 : 637 45.
16. Laan RFJM van Riel PLCM van de Putte LBA, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 1993 119 : 963 8.
17. Munkholm P Langholz E Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994 35 : 360 2.
18. Faubion WA Loftus E Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: A population based study. Gastroenterology 2001 121 : 255 60.
19. Cino M Greenberg GR. Bone mineral density in Crohn's disease: A longitudinal study of budesonide, prednisone and non-steroid therapy. Am J Gastroenterol 2002 97 : 915 21.
20. Hi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegrin. Gut 2005 54 : 78 86.
21. Allali F Breban M Porcher R, et al. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor α. Ann Rheum Dis 2003 62 : 347 9.
22. Schulte CMS Dignass AU Goebell H, et al. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology 2000 119 : 909 20.
23. Robinson RJ Krzywicki T Almond L, et al. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: A randomized controlled trial. Gastroenterology 1998 115 : 36 41.
24. Theill LE Boyle WJ Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002 20 : 795 823.
25. Gilbert L He X Farmer P, et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 2002 277 : 2695 701.
26. Lin C-L Moniz C Chambers TJ, et al. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology 1996 111 : 1263 71.
27. Ammann P Rizzoli R Bonjour J-P, et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest 1997 99 : 1699 703.
28. Franchimont N Putzeys V Collette J, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther 2004 20 : 607 14.
29. Abbas S Abu-Amer Y. Dominant-negative IκB facilitates apoptosis of osteoclasts by tumor necrosis factor-α. J Biol Chem 2003 278 : 20077 82.
30. Lügering A Schmidt M Lügering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001 121 : 1145 57.
31. Florén C.-H Ahrén B Bengtsson M, et al. Bone mineral density in patients with Crohn's disease during long-term treatment with azathioprine. J Intern Med 1998 243 : 123 6.
32. Haderslev KV Tjellesen L Sorensen HA, et al. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000 119 : 639 46.
33. Bartram SA Peaston RT Rawlings DJ, et al. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 2003 18 : 1121 7.
34. Siffledeen JS Fedorak RN Siminoski K, et al. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 2005 3 : 122 32.